The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV
- PMID: 31473903
- PMCID: PMC6814576
- DOI: 10.1007/s11904-019-00463-4
The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV
Abstract
Purpose of review: People infected with HIV through injection drug use are more likely to experience progression to AIDS, death due to AIDS, and all-cause mortality even when controlling for access to care and antiretroviral therapy. While high-risk behavior and concurrent infections most certainly are contributors, chronic immune activation, downstream metabolic comorbidities may play an important role.
Recent findings: Altered intestinal integrity plays a major role in HIV-related immune activation and microbial translocation markers are heightened in active heroin users. Additionally, greater injection frequency drives systemic inflammation and is associated with HIV viral rebound. Finally, important systemic inflammation markers have been linked with frailty and mortality in people who inject drugs with and without concurrent HIV infection. Heroin use may work synergistically with HIV infection to cause greater immune activation than either factor alone. Further research is needed to understand the impact on downstream metabolic comorbidities including cardiovascular disease. Medication-assisted treatment for opioid use disorder with methadone or buprenorphine may ameliorate some of this risk; however, there is presently limited research in humans, including in non-HIV populations, describing changes in immune activation on these treatments which is of paramount importance for those with HIV infection.
Keywords: Cardiovascular risk; HIV; Heroin; Inflammation; Opioid use disorder.
Conflict of interest statement
Conflict of Interest
COH has served on medical advisory boards for Gilead Sciences and as site PI for Gilead Sciences sponsored clinical trials.
GAM has served as a scientific consultant for Gilead, Merck, and ViiV, and had received research grants from Roche, Tetraphase, and Astellas.
References
-
- Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256–66. - PubMed
-
- Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, et al. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV medicine. 2014;15(10):595–603. - PubMed
-
-
Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV. Circulation. 2018;138(11):1100–12.
This systematic review and meta-analysis across 80 studies reports that the risk of cardiovascular disease in people living with HIV is two times higher than the general population solidifying HIV infection as an important risk factor for cardiovascular disease.
-
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
